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BACKGROUND: The current study was aimed at investigating the feasibility of hippocampus-avoidance whole-brain radiation therapy 
with a simultaneous integrated boost (HA-WBRT+SIB) for metastases and at assessing tumor control in comparison with conventional 
whole-brain radiation therapy (WBRT) in patients with multiple brain metastases. METHODS: Between August 2012 and December 2016, 
66 patients were treated within a monocentric feasibility trial with HA-WBRT+SIB: hippocampus-avoidance WBRT (30 Gy in 12 fractions, 
dose to 98% of the hippocampal volume ≤ 9 Gy) and a simultaneous integrated boost (51 or 42 Gy in 12 fractions) for metastases/ resection 
cavities. Intracranial tumor control, hippocampal failure, and survival were subsequently compared with a retrospective cohort treated 
with WBRT via propensity score matching analysis. RESULTS: After 1:1 propensity score matching, there were 62 HA-WBRT+SIB patients 
and 62 WBRT patients. Local tumor control (LTC) of existing metastases was significantly higher after HA-WBRT+SIB (98% vs 82% at 
1 year; P =  .007), whereas distant intracranial tumor control was significantly higher after WBRT (82% vs 69% at 1 year; P =  .016); this 
corresponded to higher biologically effective doses. Intracranial progression-free survival (PFS; 13.5 vs 6.4 months; P = .03) and overall 
survival (9.9 vs 6.2 months; P = .001) were significantly better in the HA-WBRT+SIB cohort. Four patients (6.5%) developed hippocampal 
metastases after hippocampus avoidance. The neurologic death rate after HA-WBRT+SIB was 27.4%. CONCLUSIONS: HA-WBRT+SIB can 
be an efficient therapeutic option for patients with multiple brain metastases and is associated with improved LTC of existing metastases, 
higher intracranial PFS, a reduction of the neurologic death rate, and an acceptable risk of radiation necrosis. The therapy has the potential 
to prevent neurocognitive adverse effects, which will be further evaluated in the multicenter, phase 2 HIPPORAD trial. Cancer 2020;126: 
2694-2703. © 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society This is an open access 
article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any 
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. 
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INTRODUCTION
Whole-brain radiation therapy (WBRT) has been for decades one of the main therapeutic options for multiple brain 
metastases.1 Although stereotactic radiosurgery (SRS) rather than WBRT is recommended for patients with 1 to 3 brain 
metastases,1,2 the optimal treatment for patients with more than 4 metastases has been recently controversially discussed. 
WBRT has the advantage of better distant intracranial tumor control (DTC) but is associated with relatively low con-
trol of existing metastases (local tumor control [LTC]) and a considerable rate of late neurocognitive adverse effects.1,3,4 
Conversely, SRS shows improved LTC but higher rates of distant intracranial tumor progression and neurologic death.1,2,5
Neurocognitive decline after WBRT can occur through hippocampal atrophy and irradiation of the neural stem cell 
niche, which is otherwise responsible for brain plasticity and repair,6 and through the applied whole-brain radiation dose, 
which can lead to long-term brain atrophy and leukoencephalopathy.7,8 Poor LTC and thus progressive brain metastases 
have also been correlated with significant neurocognitive deterioration,9-11 and this suggests that LTC plays an essential 
role in preserving cognitive functions.
An improvement of LTC after WBRT can be attained through the application of additional SRS to the metastases.12  
Furthermore, conformal hippocampus avoidance (HA) in WBRT planning was also shown to preserve memory 
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function in a phase 2, multi-institutional trial13 and 
in the first results of the randomized, phase 3 NRG 
Oncology CC001 trial.14 Combining these 2 modifica-
tions of WBRT together with a slightly reduced WBRT 
dose (with normal brain tissue being considered the 
clinical target volume [CTV]) could thus improve in-
tracranial LTC, reduce neurologic death rates, and also 
potentially have a positive impact on cognitive function.
Exploring the combination of hippocampus-avoid-
ance whole-brain radiation therapy (HA-WBRT) and 
SRS, Prokic et al15 found in a planning study that the 
best sparing of the hippocampi can be achieved if the 
dose escalation to the metastases is planned as a simul-
taneous integrated boost (SIB) rather than as sequential 
SRS. Moreover, an SIB has the biological advantage of 
dose fractionation. The current feasibility study is aimed, 
therefore, at providing the first systematic clinical infor-
mation for the compound therapeutic concept of hippo-
campus-avoidance whole-brain radiation therapy with a 
simultaneous integrated boost (HA-WBRT+SIB) and 
assessing whether it can improve intracranial LTC in 
patients with multiple brain metastases while main-
taining acceptable DTC despite dose reduction to the 
normal brain (CTV) and hippocampus protection 
(HA). The results are compared with those of a selected, 
clinically similar group of patients previously treated 
with conventional WBRT at the same institution.
MATERIALS AND METHODS
HA-WBRT+SIB Patients and Treatment
Sixty-six patients with multiple brain metastases were 
enrolled between August 2012 and December 2016 at 
the Department of Radiation Oncology of the Medical 
Center – University of Freiburg with the intention of 
undergoing HA-WBRT+SIB parallel and analogously 
to the experimental arm of the ongoing multicenter, 
phase 2 HIPPORAD trial (“Whole-Brain Irradiation 
With Hippocampal Sparing and Dose Escalation on 
Metastases: Neurocognitive Testing And Biological 
Imaging,” NOA-14, ARO 2015-3, DRKS00004598). 
The analysis was approved by the local ethics commit-
tee. Patients were included if they had at least 4 brain 
metastases of solid tumors (range, 4-16), no metastases 
within the hippocampus or within a distance of 7 mm 
from the hippocampus, and no leptomeningeal disease 
or acute neurologic symptoms demanding an imme-
diate start of radiation therapy and were not eligible 
for inclusion in the HIPPORAD trial (eg, because of 
insufficient language skills for neurocognitive testing, 
depression, or a refusal to collaborate). Prior radiation 
treatment to the brain (stereotactic fractionated radio-
therapy, 6  ×  5  Gy; radiosurgery, 20  Gy) was allowed 
if the treated areas showed local control and were not 
located in the hippocampus or within 7  mm of the 
hippocampus. Patients were treated with HA-WBRT 
(30 Gy in 12 fractions, dose to 98% of the hippocampal 
volume [D98%] ≤ 9 Gy, dose to 2% of the hippocam-
pal volume [D2%] ≤ 17Gy, mean dose ≤ 10 Gy) and 
an SIB with 51 or 42  Gy in 12 fractions (according 
to the size and location) on multiple brain metastases 
(2-16) and/or resection cavities (0-2). Pre-irradiated 
metastases or resection cavities were treated with 30 Gy 
in 12 fractions without further dose escalation.
HA-WBRT+SIB Radiation Treatment Planning
Patients underwent radiation therapy–planning computed 
tomography (CT) with a 1-mm slice thickness in ther-
moplastic mask immobilization (BrainLab, Feldkirchen, 
Germany) as well as 3-dimensional, contrast-enhanced 
sagittal T1-weighted magnetic resonance imaging 
(Gd-T1MRI). Gd-T1MRI and CT scans were rigidly 
coregistered on the basis of mutual information (iPlan 
RT Image 4.1.1; BrainLab, Feldkirchen, Germany) and 
served for the target volume and organ-at-risk delineation.
The planning tumor volume of the brain 
(PTVwhole brain) was defined as the whole brain plus 
3 mm minus the planning tumor volume of metastases 
(PTVmetastases) and the hippocampus-avoidance region 
(HAR). PTVmetastases was formed by the addition of 
1 mm to the gross tumor volume, whereas for resection 
cavities, a margin of 2 mm was added to the CTV. The 
dose was prescribed to cover the 95% isodose. HAR 
was defined as a 7-mm 3-dimensional margin around 
the hippocampus, as described previously.16 Dose 
constraints to organs at risk are presented in Table 1. 
Patients were treated with volumetric modulated arc 
therapy based on 2 to 4 arcs.
TABLE 1. Organ-at-Risk Dose Constraints 
Analogous to the HIPPORAD Trial Protocol
Organ at Risk Dose Constraint
Hippocampus D98% ≤ 9 Gy, D2% ≤ 17 Gy
Optic nerves, chiasm D98% ≤ 33 Gy
Optic nerve, 1-sided D2% ≤ 35 Gy
Retina, 1-sided D2% ≤ 33 Gy
Lenses D2% ≤ 7 Gy
Inner ear (in case of bilateral involvement) D2% ≤ 33 Gy
Brain stem D2% ≤ 33 Gy
Abbreviations: D2%, dose to 2% of the hippocampal volume; D98%, dose to 
98% of the hippocampal volume.
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WBRT Patients and Treatment
A total of 633 patients who had received conventional 
WBRT at our department between January 2005 and 
December 2011 were identified and retrospectively 
analyzed (unpublished data; Hintz, M., Freiburg, 2017, 
https://freid ok.uni-freib urg.de/data/12315; accessed 
February 18, 2020); 232 unsuitable patients were then 
excluded from further analysis (Fig. 1). WBRT was per-
formed with either conventional 2-dimensional planning 
(94.8%) or CT-based 3-dimensional planning (5.2%). 
The applied dose was on average 35 Gy (α/β for the equiv-
alent dose in 2-Gy fractions [EQD2] = 10): 30 Gy in 10 
fractions for 49.9%, 35 Gy in 14 fractions for 30.8%, and 
other for 19.3%. Starting in 2012, all patients who were 
eligible for CT-based WBRT and did not have (peri)hip-
pocampal metastases underwent HA-WBRT+SIB.
Follow-Up
The HA-WBRT+SIB cohort was scheduled for follow-
up examinations, including magnetic resonance imaging 
(MRI), physical examinations, and toxicity assessments ac-
cording to version 4.0 of the Common Terminology Criteria 
for Adverse Events (CTCAE), 6  weeks after therapy and 
every 3 months thereafter. The retrospective WBRT group 
was followed up every 3 months according to clinical routine.
Intracerebral LTC and DTC were evaluated from 
the first day of treatment. Metastases were evaluated 
along the largest diameters on Gd-T1MRI accord-
ing to Response Assessment in Neuro-Oncology Brain 
Metastases criteria.17
LTC was defined as complete remission, partial remis-
sion, or stable disease with respect to brain metastases that 
were present at the time of irradiation. Treatment-related 
changes, including pseudoprogression and radiation necro-
sis, were not considered local failures for LTC. Existing me-
tastases at the time of irradiation were deemed progressive if 
they exhibited a relative increase of at least 20% from their 
nadir or an increase by an absolute value of 5 mm or more. 
Progressive lesions were treated conservatively for 6 weeks 
with a therapy consisting of dexamethasone (3 × 4 mg/d for 
4 days followed by a 2-mg dose reduction every 2 days) and 
parallel pentoxifylline (400 mg twice a day). Pentoxifylline 
is a well-tolerated hemorrheologic methylxanthine deriv-
ative that increases blood flow and facilitates cell passage 
through microvessels; it improves oxygenation to injured 
cerebral tissue and limits inflammation by inhibiting tumor 
necrosis factor α and fibroblast growth factor 2.18-20 After 
6 weeks, a control MRI scan was performed. If no further 
progression was noted, treatment-related changes were di-
agnosed, and follow-up was continued. If a further increase 
in the contrast-enhancing lesions was seen, an intervention 
was initiated as oncologically indicated and interdiscipli-
narily decided. Histological evidence of necrosis without 
vital tumor cells in a biopsy or resection led to the diagno-
sis of radiation necrosis, whereas histological evidence of a 
tumor or the initiation of further therapy in the form of 
re-irradiation or systemic therapy crossing the blood-brain 
barrier led to the diagnosis of local failure for LTC.
Failure for DTC was defined as the unequivocal 
appearance (and progression) of a new intracerebral lesion 
(or lesions) as well as leptomeningeal spread.
Overall survival (OS) was calculated from the first day 
of irradiation until death of any cause or the day on which 
the patient was last known to be alive in the case of loss 
Figure 1. Flow diagram of the study design. HA-WBRT+SIB indicates hippocampus-avoidance whole-brain radiation therapy with a 
simultaneous integrated boost; SCLC, small cell lung carcinoma; WBRT, whole-brain radiation therapy.
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to follow-up. Progression-free survival (PFS) was calculated 
from the first day of irradiation until tumor progression or 
death of any cause or until the day on which the patient was 
last known to be alive in the case of loss to follow-up.
Assessed toxicity comprised therapy-related adverse 
events, including alopecia, radiation dermatitis, wound- 
healing disorders, cerebral edema, headache, vomiting, 
nausea, vertigo, fatigue, focal neurologic deficits, epilepsy, 
subjective concentration or cognitive impairments, and 
radiation necrosis.
Statistics
Data were analyzed with R (release 3.6.1 [2013]; R 
Foundation for Statistical Computing, Vienna, Austria) 
and RStudio (2015; RStudio, Inc, Boston, Massachusetts). 
For OS and PFS, the Kaplan-Meier method was used to 
provide median point estimates, and groups were com-
pared by means of the log-rank (Mantel-Cox) test. The 
median follow-up time was calculated with the reverse 
Kaplan-Meier method.
A propensity score matching analysis was per-
formed with a logistic regression that considered the fol-
lowing: age, sex, Karnofsky performance status, primary 
tumor, time from the first diagnosis to the diagnosis of 
brain metastases, number of brain metastases, presence 
of extracranial metastases, and concurrent systemic ther-
apies (ie, parallel to or following radiation before the 
diagnosis of further cerebral disease progression). Targeted 
therapies and immunotherapies were considered relevant 
systemic therapies. LTC and DTC were estimated with 
the Aalen-Johansen estimator for cumulative incidences, 
with death considered as a competing risk.
RESULTS
Along with the 66 patients treated with HA-WBRT+SIB, 
a total of 401 patients previously treated with WBRT were 
identified. After 1:1 matching, there were 62 patients in 
each group. Treatment groups were well balanced across 
known prognostic covariates (Table 2). There were small, 
statistically insignificant imbalances in the sex distribu-
tions, tumor types, tumor sizes, and the application of 
immunotherapy. More patients with non–small cell lung 
carcinoma were found in the WBRT group (59.7% vs 
43.5%), whereas more patients with melanoma underwent 
HA-WBRT+SIB (19.4% vs 8.1%). Also, more patients 
received immune checkpoint inhibitors in the HA-
WBRT+SIB group (8.1% vs 3.2%), and the tumor load 
was slightly larger in the WBRT cohort (87.2 vs 78.4 mm). 
The median follow-up time was 8.5 months in the HA-
WBRT+SIB group and 6.3 months in the WBRT group.
Intracranial LTC and DTC
The cumulative incidence of local intracerebral progres-
sion was significantly lower and thus the LTC of existing 
metastases was significantly higher in the HA-WBRT+SIB 
group (P = .007; 98% [95% CI, 96%-100%] vs 82% [95% 
CI, 79%-97%] at 1 year; Fig. 2A) with death as a compet-
ing risk. The crude 1-year LTC for boosted metastases was 
91.3%. The biologically effective dose (BED) to the metas-
tases was 42.1 ± 4.2 Gy (α/β = 10) for WBRT and 60.6 Gy 
(α/β = 10) for HA-WBRT+SIB (P < .00001).
At the last follow-up, there were a total of 380 
boosted lesions in the HA-WBRT+SIB cohort: 105 
(27.6%) had a complete remission, 153 (40.3%) had a 
partial remission, 47 (12.4%) were stable, and 11 (2.9%) 
were progressive. Sixty-four lesions (16.8%) in 12 patients 
did not receive MRI follow-up because the patients were 
in bad condition or died within 6  weeks of irradiation 
(extracranial tumor progression [n = 5], cardiac compli-
cations/thromboembolism [n = 3], or unclear [n = 2]) or 
were lost to follow-up (n = 2).
The probability of DTC was significantly higher in 
the WBRT group (P = .016; 82% [95% CI, 70%-92%] 
vs 69% [95% CI, 60%-82%] at 1 year; Fig. 2B). Patients 
treated with HA-WBRT+SIB received a BED to the 
whole brain (minus HAR and metastases) of 37.5  Gy 
(α/β = 10), whereas patients undergoing WBRT received 
on average 42.1 ± 4.2 Gy (α/β = 10; P < .00001). The 
EQD2 for α/β =  2 was also significantly higher in the 
WBRT group with a mean of 38.9  ±  3.5  Gy versus 
33.8  Gy in the HA-WBRT+SIB group (P  <  .00001). 
Four patients in the HA-WBRT+SIB group and 3 pa-
tients in the WBRT group had leptomeningeal disease 
progression.
The application of targeted therapies and immu-
notherapies did not influence LTC or DTC significantly 
(P = .84 and P = .56, respectively; Fig. 2C,D).
OS and Intracranial PFS
OS was significantly different between the 2 groups, with a 
median of 9.9 months for the HA-WBRT+SIB group and 
a median of 6.2 months for the WBRT group (P = .001; 
Fig. 3A). Overall intracranial PFS was also significantly 
higher in the HA-WBRT+SIB group (13.5 months) than 
the WBRT group (6.4 months; P = .03; Fig. 3B).
Forty-eight patients in the HA-WBRT+SIB group 
and 42 patients in the WBRT group received concurrent 
systemic therapies, whereas 24 and 16, respectively, received 
potentially relevant systemic therapies (for a detailed de-
scription, see Table 2). Previous treatment of brain metasta-
ses was more frequent in the HA-WBRT+SIB group than 
Original Article
2698 Cancer  June 1, 2020
the WBRT group (resection, 50% vs 14.5%; SRS, 33.9% 
vs 12.9%). Local salvage therapies (resection and radiother-
apy) were similarly used in the 2 groups (24.2% vs 21%).
By the end of the study, 61 patients in the WBRT 
group and 53 patients in the HA-WBRT+SIB group 
had died. The most probable cause of death in the 
HA-WBRT+SIB group was intracranial tumor progres-
sion in 17 cases and extracranial progression and other 
causes (eg, infection and cardiac decompensation) in 26 
cases. The cause of death was unclear in 10 cases. No reli-
able information on the cause of death could be obtained 
for the retrospective WBRT cohort.
TABLE 2. Patient Characteristics According to the Treatment Group
Patient Characteristic HA-WBRT+SIB WBRT P and d
Age, mean, y 58.34 58.02 P = .8768a 
d = 0.026
Sex, No. (%)
Male 27 (43.5) 33 (53.2) P = .3768b 
Female 35 (56.5) 29 (46.8) d = –0.195
KPS, No. (%)
90%-100% 38 (61.3) 40 (64.5) P = .69654c 
70%-80% 23 (37.1) 19 (30.6) d = –0.066d 
50%-60% 1 (1.6) 3 (4.9)  
Primary tumor, No. (%)
NSCLC 27 (43.5) 37 (59.7)  
Malignant melanoma 12 (19.4) 5 (8.1) P = .6464b 
Breast cancer 15 (24.2) 9 (14.5) d = –0.103e 
Gastrointestinal cancer 3 (4.8) 4 (6.5)  
Other 5 (8.1) 7 (11.3)  
Occurrence of brain metastases, No. (%)f 59 (95.2)/3 (4.8) 60 (96.8)/2 (3.2) P = 1.0000b 
d = –0.082
No. of cerebral metastases and resection cavities, mean (range) 5.95 (4-16) 6.39 (4-17) P = .97606c 
d = –0.047
Sum of longest diameters of cerebral metastases, mean (range), mm 78.4 (25-172) 87.2 (28-218) P = .67448c 
d = –0.188
Extracranial metastases, No. (%)
Yes 43 (69.4) 44 (71) P = 1.0000b 
No 19 (30.6) 18 (29) d = –0.035
Targeted therapy: total, No. (%)g 19 (30.6) 16 (25.8)  
Gefitinib 4 0  
Lapatinib 3 0  
Trastuzumab 7 1  
Trastuzumab emtansine 3 0  
Pertuzumab 3 0  
Sunitinib 1 3  
Sorafenib 0 1 P = .6767b 
Vemurafenib 1 0 d = 0.075
Dabrafenib 2 0  
Trametinib 2 0  
Afatinib 2 1  
Crizotinib 1 0  
Erlotinib 1 7  
Temsirolimus 0 1  
Temozolomide 0 2  
Immunotherapy: total, No. (%)g 5 (8.1) 2 (3.2)  
Ipilimumab 3 0  
Pembrolizumab 3 0 P = .3711b 
Nivolumab 1 0 d = 0.213
Interferon 0 2  
Abbreviations: d, standardized difference; HA-WBRT+SIB, hippocampus-avoidance whole-brain radiation therapy with a simultaneous integrated boost; KPS, 




dFor KPS of 90% to 100% versus KPS of 50% to 80%.
eFor NSCLC and malignant melanoma versus other.
fSynchronous (within 6 months of the first tumor diagnosis)/metachronous (later than 6 months after the first tumor diagnosis).
gMore than 1 agent per patient was possible.
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Hippocampal Failure
In the HA-WBRT+SIB group, the mean dose to the bilat-
eral hippocampi was 6.8 ± 0.5 Gy (median, 6.7 Gy; EQD2 
α/β = 2), whereas the dose to 40% of the hippocampal vol-
ume (D40%) was on average 6.7 ± 0.5 Gy (median, 6.6 Gy; 
EQD2 α/β = 2). The average D2% to the hippocampus 
was 11.2 ± 1.9 Gy (median, 10.3 Gy; EQD2 α/β = 2), and 
D98% was 5.4 ± 0.3 Gy (median, 5.4 Gy; EQD2 α/β = 2; 
Fig. 4). Five patients developed a total of 6 metastases in the 
area of hippocampal avoidance on average 5.8 months after 
irradiation: 4 (6.5%) were within the hippocampus itself, 
and 2 were in the 7-mm margin around the hippocampus. 
The actuarial rate per year was 3.6%. Each new metastasis 
in the HAR was associated with disseminated progression 
of brain metastases in the brain regions having received 
30 Gy. In the area just around the HAR with doses ranging 
between 27 and 30 Gy, new metastases appeared in 4 pa-
tients. Three of these patients had a simultaneous metastasis 
in the hippocampus and disseminated progression in the 
whole brain. In the conventional WBRT group, 3 patients 
(4.8%) developed a new metastasis in the hippocampus 
region (actuarial rate per year, 3.3%).
Figure 2. (A) Significantly lower cumulative incidence of local intracerebral progression and thus significantly higher LTC with HA-
WBRT+SIB versus WBRT (P =  .007). (B) Significantly higher cumulative incidence of distant intracerebral progression and thus 
significantly lower DTC with HA-WBRT+SIB versus WBRT (P = .016). (C) LTC and (D) DTC were not significantly influenced by the 
addition of systemic therapies crossing the blood-brain barrier (P = .84 and P = .56, respectively). DTC indicates distant intracranial 
tumor control; HA-WBRT+SIB, hippocampus-avoidance whole-brain radiation therapy with a simultaneous integrated boost; LTC, 
local tumor control of existing metastases; syst, systemic therapies; WBRT, whole-brain radiation therapy.
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Figure 3. (A) Significantly higher OS and (B) intracranial PFS with HA-WBRT+SIB versus WBRT (P = .001 and P = .03, respectively). 
HA-WBRT+SIB indicates hippocampus-avoidance whole-brain radiation therapy with a simultaneous integrated boost; OS, overall 
survival; PFS, progression-free survival; WBRT, whole-brain radiation therapy.
Figure 4. Example of a dose distribution and dose-volume histogram of an HA-WBRT+SIB plan for a patient with 15 brain metastases. 
Colors indicate the following: blue, hippocampi; purple, HAR; orange, PTVwhole brain (whole brain + 3 mm − HAR − PTVmetastases); pink, 
PTVmetastases; green, brainstem; and yellow, optic chiasm. The mean dose in both hippocampi remained under 10 Gy, whereas the 
whole brain and the metastases received means of 30 and 51 Gy, respectively. The 1-year magnetic resonance imaging follow-up 
showed complete remission of the metastases. Arrows indicate three of the metastases before and after therapy. HAR indicates 
hippocampus-avoidance region; HA-WBRT+SIB, hippocampus-avoidance whole-brain radiation therapy with a simultaneous 
integrated boost; PTVmetastases, planning tumor volume of metastases; PTVwhole brain, planning tumor volume of the whole brain.
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Toxicity of HA-WBRT+SIB
In the HA-WBRT+SIB cohort, 2 patients described a sub-
jective memory decline. Adverse events higher than grade 
2 (according to the National Cancer Institute’s CTCAE, 
version 4.03) were observed in 4 patients (6.5%): 1 grade 
4 epileptic seizure, 1 grade 3 case of radiation necrosis, 
and 2 grade 3 intrametastatic hemorrhages in 2 patients 
with malignant melanoma. All patients experienced grade 
2 alopecia. One patient had a CTCAE grade 2 case of 
radiation necrosis treated with bevacizumab.
Therapy-related changes with transient enlargement 
due to central tumor necrosis, with a gradual return to 
the initial volume under corticosteroid and pentoxifyl-
line therapy, were observed in 25 of 380 boosted lesions 
(6.6%). Five further lesions were progressive despite a 
corticosteroid and pentoxifylline treatment and were 
either resected (4 of 5) or biopsied (1 of 5) to differentiate 
progression from radiation necrosis. In 2 of these cases 
(the biopsy and 1 of the 4 resections), radiation necrosis 
was confirmed without evidence of vital tumor cells. In 
the retrospective WBRT cohort, toxicity data could not 
be reliably collected.
DISCUSSION
The aim of this study was 2-fold: 1) to prospectively assess 
the clinical efficacy and feasibility of HA-WBRT+SIB in 
patients with multiple brain metastases and 2) to explore 
how intracranial LTC compares with LTC for patients 
treated with conventional WBRT. Data on 20 patients 
treated similarly were published in 2015, and they sug-
gested favorable intracranial tumor control rates.16 The 
current study assessed a total of 62 patients, the largest 
cohort to date treated with HA-WBRT+SIB, and it is the 
first study comparing HA-WBRT+SIB with WBRT.
In an era of more efficient local and systemic ther-
apies and improved survival rates, the preservation of 
neurologic and neurocognitive function becomes all 
the more important. Several prospective clinical trials 
have described a correlation between intracranial tumor 
progression and neurocognitive impairment and sub-
sequently altered quality of life.9,11,21,22 All in all, in-
tracranial tumor control proved to be very good in the 
highly selected cohort of patients treated with conven-
tional WBRT. However, in the HA-WBRT+SIB group, 
the LTC of existing metastases was significantly higher, 
and this was also reflected in improved intracranial PFS. 
The 1-year LTC rate of 91.3% for boosted metastases 
was comparable to that obtained after SRS alone.5,23,24 A 
similar improvement in LTC through dose escalation to 
metastases was shown in a meta-analysis by Patil et al,25  
who explored the combination of WBRT and SRS. In 
comparison, dose escalation through SIBs has the bio-
logical advantage of fractionation for both normal and 
tumor tissue and ensures better HA.14 The combination 
with relevant systemic therapies, including novel immune 
checkpoint inhibitors, did not alter tumor control signifi-
cantly, but a definite statement is not possible because of 
the low number of patients involved.
The occurrence of new intracranial metastases, how-
ever, was significantly lower in the WBRT group, and this 
was related to a significantly higher BED applied to the 
whole brain. This suggests a dose-dependent potential of 
WBRT for preventing new metastases. Several random-
ized trials26-32 have analyzed various dose-fractionation 
schedules for WBRT and compared them with the stan-
dard 30 Gy in 10 fractions (BED = 39 Gy; α/β = 10). 
Although no evidence for improved survival with a higher 
BED was given, a lower BED proved significantly less 
efficient.1 However, lower total doses and doses per frac-
tion, assessed especially in the context of prophylactic 
cranial irradiation, showed lower incidences of neurocog-
nitive impairment.33 Other late toxicities, including brain 
atrophy and leukoencephalopathy, characterized inter alia 
by neurocognitive dysfunction, also become more preva-
lent with higher total doses of radiotherapy.7,8,34,35 Thus, 
the lower dose prescribed to the whole brain in the HA-
WBRT+SIB cohort takes into consideration the multiple 
SIBs and the smaller prescription volume (PTVwhole brain − 
PTVmetastases  −  HAR) in order to potentially minimize 
neurocognitive adverse effects, but it also comes with the 
trade-off of possibly lower DTC. Assessing the risk-bene-
fit ratio in this case remains an endeavor for the clinician.
The lower DTC could not be attributed to the HA, 
and this supports the idea that HA-WBRT is a safe treat-
ment concept. Tumor progression in the HAR was ob-
served in only 8.1% of the cases, and each new metastasis 
in this area was associated with disseminated distant pro-
gression in the brain regions receiving 30 Gy. Gondi et al36 
previously explored the risk of developing perihippocam-
pal metastases after HA-WBRT in the phase 2 Radiation 
Therapy Oncology Group 0933 trial and identified 8.6% 
to 12.1% of patients as presenting with metastases within 
5 to 10 mm of the hippocampus. Oehlke et al16 similarly 
reported new hippocampal metastases in 10% of cases.
The dose constraints for the HAR were analogous 
to those in the ongoing randomized, multicenter, phase 
2 HIPPORAD trial. D98% for the bilateral hippocampi 
was lower than 9 Gy, D2% was lower than 17 Gy, and 
D40% was lower than 7.3 Gy. These values are also con-
sistent with the constraints of the Radiation Therapy 
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Oncology Group 0933 trial12 and the subsequent phase 
3 NRG Oncology CC001 trial as well as the dosimetric 
analysis of Gondi et al.37 The latter indicated that neuro-
cognitive function impairment was associated with 40% 
of the bilateral hippocampi having received more than 
7.3 Gy. When we take this into consideration, the HA 
achieved in our study is most likely able to prevent signif-
icant hippocampus-related cognitive impairment.
The acute toxicity profile of HA-WBRT+SIB 
also proved acceptable and was derived primarily from 
the SIB. Serious adverse events within the first year of 
follow-up were comparable in type and frequency (6.5%) 
to those following SRS alone. Yamamoto et al24 prospec-
tively investigated 1194 patients treated with multiple 
SRS treatments and reported SRS-induced adverse events 
in 6% to 8% of their patients.
The OS of patients treated with HA-WBRT+SIB 
was significantly higher than the OS of the propensi-
ty-score-matched cohort of patients treated with conven-
tional WBRT. After we matched accounting for known 
confounders, the 2 groups differed clearly only in terms of 
the year of therapy (2005-2011 vs 2012-2017). When we 
consider recent advances in immune and targeted thera-
pies, the observed improvement in OS was most likely a 
result of more effective systemic therapies. However, a sim-
ilar impact on survival of further dose escalation through 
sequential SRS after WBRT was previously shown by 
Andrews et al.12 Hence, an additional benefit of the im-
proved LTC for survival cannot be completely excluded. 
The neurologic death rate, defined as the rate of intra-
cranial failure as a component of the cause of death, was 
27.4%. This rate is similar to the previously reported rate 
of 28% after WBRT combined with surgery/SRS2 and 
shows an improvement in comparison with surgery/SRS 
alone (44%) and also historical WBRT cohorts (36%).2,12
A major limitation of this study is that a structured 
neurocognitive assessment was not performed. Major de-
pression, anxiety, and fatigue are often diagnosed in pa-
tients with advanced cancer and can have a significant 
influence on neurocognitive function, as shown previ-
ously.38,39 To correctly address these aspects, a thorough 
neurocognitive evaluation will be performed in the pro-
spective HIPPORAD trial. A further limitation is the 
1:1 matched propensity score design, which still retained 
slight imbalances and might have been stronger if it had 
been a 2:1 design, had a larger number of patients been 
available. Because HA-WBRT+SIB is a new irradiation 
method for a highly selected category of neurologically fit 
patients with multiple cerebral metastases without menin-
geal spread, this remains the largest cohort to date treated 
in this manner. The propensity score matching analysis 
may also have ignored certain confounders, such as applied 
molecular therapy or immunotherapy, which have signifi-
cantly changed in the past years. Although this difference 
most likely had an impact on survival, it did not seem to 
influence intracranial tumor control. However, this has to 
be investigated in a larger number of patients, with special 
consideration given to the histology of the primary tumor 
and the systemic therapy. Because the 2 cohorts in our 
study were chronologically shifted, there is a low proba-
bility of further significant differences between the groups.
In conclusion, HA-WBRT+SIB can be an effective 
therapeutic option for patients with multiple brain me-
tastases and shows improved LTC of existing metastases 
and improved overall intracranial PFS in comparison 
with WBRT alone. However, intracranial DTC appears 
higher after conventional WBRT. These clinical results 
support the correlation between BED and tumor control 
in brain metastases. The potential of HA-WBRT+SIB to 
prevent neurocognitive effects will be further evaluated in 
the randomized, multicenter, phase 2 HIPPORAD trial 
(NOA-14, ARO 2015-3, DRKS00004598).
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